Zoetis (ZTS) Q2 2026 earnings review
Guidance Slashed as U.S. Companion Animal Weakness Deepens
Zoetis's Q2 results confirm the worst fears of the prior quarter: the U.S. pet care market is undergoing a structural contraction. Revenue was completely flat year-over-year at $2.47B (-1% organically), while Adjusted Net Income reversed to a 1% reported decline. While the global Livestock business provided a spectacular buffer (+10% organic growth), it could not mask the 11% freefall in U.S. Companion Animal sales. Management responded by drastically cutting FY26 guidance, lowering the organic revenue growth forecast from a positive 2-5% to a negative 1-3%. The core thesis of a resilient, premium-priced animal health monopoly is cracking under the weight of price-sensitive consumers and aggressive generic competition.
🐂 Bull Case
The Livestock segment is accelerating, posting 23% revenue growth in the U.S. and 8% internationally. The business is heavily benefiting from favorable cattle economics and targeted poultry vaccine demand.
Management reduced SG&A expenses by 4% to $592 million in Q2. They are aggressively pulling cost levers to protect margins and earnings against the top-line shortfall.
🐻 Bear Case
U.S. Companion Animal revenue collapsed 11% year-over-year for the second consecutive quarter. Pet owner price sensitivity and lower clinic traffic are devastating demand for premium products.
For the first time, management explicitly cited generic competition hitting legacy blockbuster brands Cerenia and Convenia, compounding the pressure already felt in the dermatology and parasiticide franchises.
⚖️ Verdict: 🔴🔴
Bearish. Management's Q1 narrative that the weakness was a temporary 'bridge' has evaporated. A massive guidance cut and the admission of generic erosion indicate the core growth engine is broken for the foreseeable future.
Key Themes
U.S. Companion Animal Structural Decline
The U.S. Companion Animal segment remains stable at a highly negative trajectory, declining 11% in Q2 following an 11% drop in Q1. Key franchises, specifically dermatology and Simparica Trio, are facing persistent macro-driven price sensitivity. Customers are pushing back against years of veterinary clinic price hikes, shifting demand away from Zoetis's premium portfolio.
Guidance Collapse Contradicts Q1 Narrative
In Q1, management framed the weakness as a temporary 'bridge' to a 2027 innovation cycle and guided for an aggressive second-half ramp (2-5% full-year organic growth). Q2 completely contradicts this narrative. FY26 guidance was decimated to negative 1-3% organic growth. This exposes a severe miscalculation of market elasticity and competitive intensity by management.
Generic Competition Materializing
Zoetis historically traded at a premium due to the perceived 'stickiness' of its veterinary brands against generics. This quarter, management explicitly cited generic competition impacting the Cerenia and Convenia brands as a primary headwind. This is a fundamental break in the investment thesis that requires close monitoring.
Livestock Business Accelerating
Livestock continues to be the ultimate hedge, growing 12% globally on a reported basis (10% organic). The U.S. segment was particularly explosive, accelerating to 23% YoY growth driven by favorable producer economics in beef cattle and well-timed poultry vaccine sales tied to disease outbreaks.
International Companion Animal Resilience
While the U.S. falters, International Companion Animal remains stable, growing 8% reported (5% organic). Growth is anchored by the parasiticides portfolio (Simparica Trio) and early contributions from the international launches of new osteoarthritis pain treatments Lenivia and Portela.
Diagnostic and AI Teleradiology Expansion
Zoetis is aggressively shifting focus toward sticky, service-based revenue. The completion of the VitalRADS acquisition pushes the company into veterinary teleradiology. Combined with the launch of the AI-powered Vetscan Opticell hematology analyzer, Zoetis is building a 'Virtual Reference Lab' ecosystem to capture diagnostic spend inside the clinic.
Other KPIs
Stable. Calculated from $1.79B in adjusted gross profit on $2.46B in revenue. Despite severe volume deleverage in the high-margin U.S. Companion Animal business, margins held up, likely due to favorable international mix, livestock pricing, and early benefits from the cost and productivity program.
Decelerating. Dropped 3% reported (4% organically) year-over-year. Management is actively throttling discretionary spending to shield the bottom line from the revenue collapse, a necessary tactical move to maintain leveraged P&L dynamics.
Guidance
Reversing. Drastically reduced from the prior range of $9.680B - $9.960B. The new midpoint implies a reported YoY decline, driven by an organic operational growth assumption of (3)% to (1)%. This indicates management expects the U.S. market contraction to persist and potentially worsen through the end of the year.
Reversing. Slashed from the prior forecast of $2.870B - $2.950B. The organic operational growth metric is now guided to plummet between (9)% and (5)%, wiping out years of steady mid-single-digit earnings expansion.
Reversing. Cut sharply from the previous $6.85 - $7.00 range. Despite a heavy $1.75B share repurchase program executed in late 2025 that artificially supports the per-share metrics, the sheer magnitude of the operational earnings decline could not be masked.
Key Questions
Structural Degradation vs Cyclical Trough
You drastically cut FY26 guidance, abandoning the Q1 narrative of an expected H2 recovery. What specific data points changed between May and August to convince you this is a structural re-basing of the pet health market rather than a cyclical inventory issue?
Generic Erosion Trajectory
With Cerenia and Convenia now explicitly facing generic pressure, what is the modeled revenue drag for these legacy franchises in the back half of the year, and how quickly do you expect them to lose market share compared to human pharma cliff events?
Cost Program Targets
Given the severity of the revenue downgrade, is the 'comprehensive cost and productivity program' announced in Q1 being upsized? How much deeper can you cut SG&A before it begins to impact commercial execution against rising competitive threats?